42nd Annual J.P. Morgan Healthcare Conference

Yvonne Greenstreet, MBChB
Chief Executive Officer

January 8, 2024

Alnylam Forward Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, expectations regarding Alnylam's aspiration to become a top-tier biotech company and the planned achievement of its "*Alnylam P^{5}x25*" strategy, the potential for Alnylam to identify new potential drug development candidates and advance its research and development programs, Alnylam's ability to obtain approval for new commercial products or additional indications for its existing products, and Alnylam's projected commercial and financial performance, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to Alnylam's ability to successfully execute on its "*Alnylam P^{5}x25*" strategy; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates, including topline results from the Company's HELIOS-B Phase 3 study of vutrisiran; actions or advice of regulatory agencies and Alnylam's ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam's ability to successfully expand the approved indications for AMVUTTRA in the future; Alnylam's ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam's business, results of operations and financial condition and the effectiveness or timeliness of Alnylam's efforts to mitigate the impact of the pandemic; Alnylam's ability to maintain strategic business collaborations; Alnylam's dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the potential risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent periodic report (Quarterly Report on Form 10-Q or Annual Report on Form 10-K) filed with the SEC and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of the date of this presentation and should not be relied upon as representing Alnylam's views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Alnylam®

Leader in RNAi Therapeutics

On Track to Become Top-Tier, Self-Sustainable Biotech by End of 2025

OUTSTANDING R&D PRODUCTIVITY

- Validated new class of medicines
- **5** medicines approved in < 4 years

LEADING COMMERCIAL CAPABILITIES

- **>$1 BILLION** generated in annual product sales
- **>60** countries with commercial presence through direct or distributor sales

ROBUST AND HIGH-YIELDING PIPELINE

- **15** clinical programs across rare, specialty, and prevalent diseases
- Up to **15** additional programs expected in clinic by end of 2025

STRONG FINANCIAL POSITION

- **>$2 BILLION** cash balance
- On path toward financial self-sustainability

Alnylam®

2023 Delivered Strong Progress Across the Business

Driving Robust Product Growth

onpattro® (patisiran) lipid complex injection 10 mg/5 mL

amvuttra® (vutrisiran) injection 25 mg/0.5 mL

GIVLAARI® (givosiran) injection for subcutaneous use 189 mg/mL

OXLUMO® (lumasiran) for injection 94.5 mg/0.5 mL

Combined net product revenues of
$1,241 million*
(39% growth YoY)



Over
5,000
patients on Alnylam commercial medicines

Extending RNAi Leadership

Human Proof of Concept for RNAi therapeutics in CNS

KARDIA-1

Positive **zilebesiran** Phase 2 results in patients with mild-to-moderate hypertension



Preclinical delivery to
new tissue types
(adipose and muscle)

55 medical publications, including
14 in high-impact^ journals

The NEW ENGLAND JOURNAL of MEDICINE

nature

Building a Sustainable Business

Landmark partnership to maximize global opportunity for **zilebesiran** in hypertension

Roche

$

Maintained strong financial position
$2.4 billion in cash
at year-end 2023*

FAST COMPANY Most Innovative Companies 2023

Science 2023 TOP EMPLOYERS

The Boston Globe TOP PLACES TO WORK 2015-2023

Continued recognition of
award-winning culture

* Preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2024. ^ Defined as Impact Factor (IF) > 10.

Alnylam®

STRONG COMMERCIAL GROWTH

ROBUST & HIGH-YIELD R&D PIPELINE

SUSTAINABLE INNOVATION ENGINE

Alnylam



STRONG COMMERCIAL GROWTH

ROBUST & HIGH-YIELD R&D PIPELINE

SUSTAINABLE INNOVATION ENGINE

Alnylam

Strong Commercial Performance, Well Positioned for Exceptional Growth

Transformational Medicines Delivering $1,241 Million in Annual Product Revenues in 2023*

Robust 39% 2023 YoY Growth* in Total Net Product Revenues



TTR Franchise

40%*

YoY growth in TTR franchise revenues

>4,060

Patients in TTR franchise globally

Ultra-Rare Franchise

35%*

YoY growth in ultra-rare franchise revenues

>1,080

Patients in ultra-rare franchise globally

* Preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2024

Alnylam®



STRONG COMMERCIAL GROWTH

ROBUST & HIGH-YIELD R&D PIPELINE

SUSTAINABLE INNOVATION ENGINE

Alnylam

Advancing a Robust and High-Yielding Pipeline of RNAi Therapeutics

Positioned to Deliver Strong Growth and Innovation Across Multiple Disease Areas and Indications

IND-enabling

ALN-HTT02*
Huntington's Disease

ALN-SOD1‡
Amyotrophic Lateral Sclerosis

ALN-Gene A
Bleeding Disorders

ALN-Gene Y
Type 2 Diabetes Mellitus

Phase 1

ALN-TTRsc04
ATTR Amyloidosis

ALN-KHK
Type 2 Diabetes Mellitus

ALN-APP*
Alzheimer's Disease

ALN-PNP†
NASH

ALN-BCAT
Hepatocellular Carcinoma

Phase 2

Zilebesiran*
Hypertension

ALN-HSD^
NASH

Elebsiran‡
(ALN-HBV02/VIR-2218)
Hepatitis B Virus Infection

Elebsiran‡
(ALN-HBV02/VIR-2218)
Hepatitis D Virus Infection

Belcesiran^
Alpha-1 Liver Disease

ALN-APP*
Cerebral Amyloid Angiopathy

Phase 3

Vutrisiran
ATTR Amyloidosis with CM

Fitusiran^
Hemophilia

Cemdisiran
(pozelimab combo)^
Myasthenia Gravis

Cemdisiran
(pozelimab combo)^
Paroxysmal Nocturnal Hemoglobinuria

Approved

onpattro® (patisiran) lipid complex injection 10 mg/5 mL

amvuttra® (vutrisiran) injection 25 mg/0.5 mL

GIVLAARI® (givosiran) injection for subcutaneous use 189 mg/mL

OXLUMO® (lumasiran) for injection 94.5 mg/0.5 mL

LEQVIO® ^ (inclisiran) injection 284 mg/1.5 mL

* Partnered, Alnylam-led with profit split † Partner-led with profit split ‡ Partner-led with Alnylam option for profit split ^ Partner-led with Milestones/Royalties
ALN-APP is awaiting CTA approval to begin Phase 2 in CAA

Alnylam®

ATTR Amyloidosis

Rare, Progressively Debilitating, and Fatal Disease

Description

Caused by a misfolded transthyretin (TTR) protein that accumulates as amyloid deposits in multiple tissues including heart, nerves, and GI tract[1]

Hereditary ATTR (hATTR) Amyloidosis

~50,000

patients worldwide[2]

Wild-Type ATTR (wtATTR) Amyloidosis

~200,000–300,000

patients worldwide[3]



1. Coelho T, et al. *N Engl J Med*. 2013;369(9):819-829
2. Ando, et al. *Orphanet J Rare Dis*, 2013; Ruberg, et al. *Circulation*, 2012 (includes hATTR amyloidosis patients with polyneuropathy and cardiomyopathy); Gertz, et al. *Am J Manag Care*. 2017;23:S107-S112
3. Information based on Alnylam modeling data

Alnylam®

RNAi Therapeutics Deliver Rapid Knockdown of Disease-Causing TTR Protein

Change from Baseline in Serum TTR Levels*



- TTR deposition in tissue of ATTR patients causes irreversible damage and premature death[1]
- RNAi mechanism drives **rapid knockdown** of TTR
- Majority of HCPs say that speed of reaching 80% mean serum TTR reduction impacts treatment consideration[2]

* Data from HELIOS-A Phase 3 study of vutrisiran; 1. Hawkins et al., Ann Med. 2015;47(8):625-38; 2. Market research with U.S. HCPs (n=40)

Alnylam®

Rapid Knockdown Results in Transformative Profile in hATTR Amyloidosis with Polyneuropathy



Strong Commercial Uptake

GROWTH

- Approaching $1 billion in annual revenues
- >4,060 patients on commercial ONPATTRO or AMVUTTRA globally

LEADERSHIP

- >90% estimated U.S. market share
- >80% estimated market share in Japan and Europe

mNIS+7, modified Neuropathy Impairment Score +7; Norfolk QOL-DN, Norfolk Quality of Life-Diabetic Neuropathy; LS, least squares; SEM, standard error of the mean.
The figures show LS mean change over time based on MMRM analysis in the overall population

Exceptional Growth Potential in ATTR-CM Market



Source: Internal Market research * U.S. Census, elderly population defined as 65+

Vutrisiran HELIOS·B Phase 3 Study

Randomized, Double-Blind Outcomes Study in ATTR Amyloidosis Patients with Cardiomyopathy

N = 655

Patient Population

- ATTR amyloidosis; wild-type or any TTR mutation
- Confirmed cardiomyopathy and medical history of symptomatic heart failure
- NYHA ≤ III; minimum walk and NT-proBNP limits at baseline

1:1 RANDOMIZATION

Vutrisiran
SC q3M
25 mg

or

Placebo
SC q3M

Primary Endpoint

- Composite outcome of all-cause mortality and recurrent CV events (when last patient reaches Month 30)

Select Secondary Endpoints

- 6-MWT distance
- Kansas City Cardiomyopathy Questionnaire (KCCQ OS) score
- Echocardiographic parameters
- All-cause mortality & recurrent all-cause hospitalizations & urgent HF visits
- All-cause mortality
- Recurrent CV events
- NT-proBNP

Topline results expected **early 2024**

HELIOS·B

ClinicalTrials.gov Identifier: NCT04153149

Alnylam®

HELIOS-B Positioned to Deliver Outcomes Benefit in ATTR-CM

Supportive Data from Patisiran in APOLLO-B

Evidence for Disease Stabilization



Reduction in Disease Biomarkers



Early Separation of Mortality Curves



Design

- **Designed and powered** to deliver **outcomes;** ~2x as large and ~3x as long as APOLLO-B
- **Enriched for patients most likely to benefit**, excluding advanced NYHA III and IV
- **Longest follow-up of any ATTR-CM study** (36 months in most patients)
- Analyses planned to demonstrate **consistency of effect across key subgroups**

Execution

- **Overenrolled** by ~10%
- **Tafamidis baseline** sub-group **lower than target of 50%**
- **Low rate** of tafamidis drop-ins, well within expectations

No significant difference in mortality was observed in APOLLO-B. The FDA issued a Complete Response Letter to the sNDA for patisiran for treatment of the cardiomyopathy of ATTR amyloidosis. Patisiran has not been approved by the FDA, EMA, or any other regulatory agency for cardiac manifestations of amyloidosis. No conclusions can or should be drawn regarding its safety or effectiveness in this population.

Alnylam®

If Approved, Vutrisiran Expected to Have Market-Leading Profile in ATTR-CM

Majority of HCPs say that **speed of reaching 80% mean serum TTR reduction** impacts treatment consideration[1]

HCPs report that **~75% of patients** treated with tafamidis have only **partial or no response**[2]

Nearly **twice as many patients** indicated they would **prefer quarterly HCP-administration** vs. monthly self-administration[3]



Unique MOA

- Highly **targeted RNAi-based mechanism** enables **rapid knockdown** of TTR
- Reduces pathogenic protein production, acting **upstream of approved medicines**

Potential for Impactful Clinical Profile

- Reduction in **mortality** and **CV hospitalizations**
- Halting decline in **functional capacity** and **quality of life**
- **Well tolerated safety profile**



Only 4 Doses per Year

- **Quarterly dosing** that aligns with doctor visits and promotes strong adherence

1. Market research with U.S. HCPs (n=40). 2. Market research with HCPs (n=530). 3. Market research with ATTR patients (n=205).

Note: The safety and efficacy of AMVUTTRA (vutrisiran) for the treatment of the cardiomyopathy of ATTR have not been established or evaluated by the FDA, EMA or any other health authority. The information is intended to provide an overview of the potential clinical profile of vutrisiran in ATTR-CM

Alnylam®

Profile of Vutrisiran Expected to Support First-Line Positioning in ATTR-CM



Note: The safety and efficacy of AMVUTTRA (vutrisiran) for the treatment of the cardiomyopathy of ATTR have not been established or evaluated by the FDA, EMA or any other health authority. Pending positive HELIOS-B study results and regulatory approval.

Source: Internal Market research. LOE: loss of exclusivity.

Alnylam®

Expanding TTR Leadership with ALN-TTRsc04

Initial Phase 1 Results Support Best-in-Class Profile



- Single 300mg dose resulted in **rapid, deep, and durable knockdown** of serum TTR:
  - **>90%** at Day 15
  - **97%** at Day 29
  - **93%** at Day 180
- All doses of ALN-TTRsc04 **well tolerated** to date; no adverse events considered related to study drug by investigator
- Data support **potential for annual subcutaneous dosing**

Phase 1 study ongoing

Phase 3 study initiation in ATTR-CM expected **at or around year-end 2024**

Alnylam®

Uncontrolled Hypertension is a Global Health Crisis

Leading Preventable Risk Factor for Cardiovascular Morbidity and Mortality

Number of Patients (7 Major Markets)



	Risk Reduction per 10 mm Hg Decrease in SBP*
Major CV Events	20%
CHD	17%
Stroke	27%
HF	28%
Renal Failure	5%
All Cause Mortality	13%

Targeting Tonic BP Control to Reduce Cardiovascular and Renal Risks



* Ettehad D, et al. *Lancet* 2016; 387: 957–67.

Alnylam®

Zilebesiran Data Support Potential to Transform Treatment of Hypertension

KARDIA-1 Phase 2 Results: Single Doses Reduced Blood Pressure Out to Six Months

Robust 24-hour Mean SBP Reduction



24-hour Tonic BP Control Maintained Out to Month 6



- Generally well tolerated
- Low incidence of AEs of ISR, hyperkalemia, and hypotension, which were mild or moderate in severity and transient; most did not require therapeutic intervention

* *p<0.0001;* Blood pressure assessments were censored if taken while patients were receiving or within 2 weeks after stopping any rescue medication. Data points are staggered for visualization; Zilebesiran is an investigational RNAi therapeutic for the treatment of hypertension; 1. Bakris et al. AHA Scientific Sessions 2023; [a] Adjusted 95% CIs and p values for the Month 3 primary analysis are based on Dunnett's test; BL, baseline; CI, confidence interval; LSM, least-squares mean; LSMD, LSM difference; Q3M, every 3 months; Q6M, every 6 months; SBP, systolic blood pressure; AEs, adverse events; ISR, injection site reaction.

Exploring Benefits of Tonic BP Control to Reduce CV Risk

Comprehensive Zilebesiran Development Plan to Reimagine Treatment of Hypertension

Phase 1 ✓

Zilebesiran safety, tolerability, and PK/PD in patients with mild-to-moderate hypertension[1]



Phase 2

KARDIA-1 ✓

Zilebesiran monotherapy in patients with mild-to-moderate hypertension

Results presented at AHA Nov 2023

KARDIA-2

Zilebesiran in combination with single antihypertensive in patients with mild-to-moderate hypertension

Topline results expected early 2024

KARDIA-3

Zilebesiran in combination with ≥2 antihypertensives in high CV risk patients with uncontrolled hypertension

Initiation expected early 2024

Phase 3

Cardiovascular Outcomes Trial (CVOT)

Study in patients with uncontrolled hypertension at high CV risk, evaluating MACE-type endpoint

Launch with label to reduce cardiovascular morbidity and mortality

Expected ~2030

The safety and efficacy of zilebesiran have not been established or evaluated by the FDA, EMA or any other health authority. Launch assumes positive clinical trial results and regulatory approval. MACE, major adverse cardiovascular event; 1. Desai AS, et al. *N Engl J Med*. 2023;389:228-238

Alnylam®

Expanding Beyond Liver with First CNS Program in Clinic

ALN-APP Has Potential to Address Multiple Patient Populations with High Unmet Need



APP: One target, two distinct pathological processes

- ☑ Genetically validated target for CAA and AD
- ☑ Upstream of Aβ42 and Aβ40, pathogenic proteins involved in CAA and AD
- ☑ Significant patient population with high unmet need in both diseases
  - CAA: Second leading cause of intracerebral hemorrhage
  - AD: Over 5M people affected in U.S. (over 30M worldwide)

Cerebral Amyloid Angiopathy (CAA)

- APP mutations cause hereditary CAA
- Amyloid deposits in walls of vessels in CNS and results in cerebral hemorrhages and cognitive impairment

Alzheimer's Disease (AD)

- APP mutations and duplications cause Early Onset AD
- Amyloid deposits in brain tissue, tau tangles in neurons, neurodegeneration

APP Protein Structure courtesy of David S. Goodsell and the RCSB Protein Data Bank; APP: amyloid precursor protein; ALN-APP is an investigational RNAi therapeutic for the treatment of CAA and AD.

Alnylam®

ALN-APP Achieved Rapid and Durable Reductions in Key Biomarkers

Phase 1 Results* Mark First Demonstration of Gene Silencing by RNAi Therapeutics in Human Brain

Rapid and Durable Reductions in CSF sAPPβ



- Generally well tolerated
- AEs generally mild to moderate in severity; most unrelated to study drug
- CSF safety biomarkers, routine lab assessments, and preliminary data for exploratory biomarker neurofilament light chain (NfL) all continued to show no concerning trends

Marked Reductions in CSF Aβ42 and Aβ40 at Month 2



Dose escalation in Phase 1 Part A **ongoing**

Multi-dose Part B
initiating in approved regions

Phase 2 CAA study initiation
planned for **early 2024**

* Data presented at 16th Clinical Trials on Alzheimer's Disease (CTAD) conference, October 2023

Alnylam®

Additional Value Creation Opportunities via Partnered Programs

FITUSIRAN

Hemophilia

Innovative approach to hemophilia A and B, with or without inhibitors

- Demonstrated reduction in annualized bleed rate across multiple Phase 3 studies
- NDA submission expected **2024**

sanofi

ELEBSIRAN (ALN-HBV02/VIR-2218)

Hepatitis B/D Virus Infection

Potential for functional cure of chronic HBV infection and chronic suppressive therapy for HDV infection

- Demonstrated robust reductions in HBsAg and potent antiviral activity in HDV
- Additional Phase 2 readouts expected in **2024**
- Alnylam opt-in right to elebsiran prior to Phase 3

VIR

CEMDISIRAN/POZELIMAB

Complement-Mediated Diseases

Unique siRNA/antibody combination providing potent C5 inhibition

- Demonstrated unprecedented LDH reduction in naïve patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Phase 3 studies in Myasthenia Gravis and PNH **ongoing**
- Phase 3 in Geographic Atrophy **initiating in 1H24**

REGENERON

ALN-HSD and ALN-PNP

Nonalcoholic Steatohepatitis

Novel approach to NASH leveraging genetically validated targets

- Demonstrated improvement in biopsy-derived NAFLD Activity Score in NASH patients with ALN-HSD
- ALN-HSD Phase 2 and ALN-PNP Phase 1 studies **ongoing** in NASH patients

REGENERON

Alnylam®



STRONG COMMERCIAL GROWTH

ROBUST & HIGH-YIELD R&D PIPELINE

SUSTAINABLE INNOVATION ENGINE

Alnylam

Organic Product Engine Capable of Sustaining Innovation for Future Growth



- Derisked platform with highly differentiated features:
  - ✓ Rapid knockdown
  - ✓ Clamped pharmacology
  - ✓ Extended durability
  - ✓ Favorable safety profile
- Modular and reproducible approach to drug development
- Historical probability of clinical success multiples higher than industry standards, driven by human genetics

Alnylam®

Multiple Sources of Sustainable Innovation Drive Robust Pipeline

Targeting Nine Alnylam-Led INDs Across Four Tissues by End of 2025

Extrahepatic Delivery



Platform Designs



IKARIA™

Reversir™



GEMINI™

Human Genetics



+ Our Future Health

discoverme

biobank uk

By End of 2025



5 new **liver** INDs

10+ including partnered programs



2 new **CNS** INDs

3+ including partnered programs



2 **new tissues** with INDs

Alnylam®

Alnylam 2024 Goals

			Early	Mid	Late
onpattro (patisiran) amvuttra (vutrisiran) GIVLAARI (givosiran) OXLUMO (lumasiran)		*Combined Net Product Revenue Guidance to be Provided at Q4/YE 2023 Earnings*			●
VUTRISIRAN	ATTR Amyloidosis	HELIOS-B Topline Results	●		
		sNDA Submission		●	
ALN-TTRsc04*	ATTR Amyloidosis	Initiate Phase 3 ATTR-CM Study			●
ZILEBESIRAN*	Hypertension	KARDIA-2 Phase 2 Topline Results	●		
		Initiate KARDIA-3 Phase 2 Study	●		
ALN-APP*	Alzheimer's Disease	Interim Phase 1 Part B Multi-Dose Results			●
		Initiate Phase 2 Study			●
	Cerebral Amyloid Angiopathy	Initiate Phase 2 Study	●		
ALN-KHK*	Type 2 Diabetes	Initiate Phase 1 Part B	●		
ALN-BCAT*	Hepatocellular Carcinoma	Initiate Phase 1 Study	●		
ADDITIONAL PROGRAMS		File 3 New INDs			●
KEY PARTNER-LED PROGRAM MILESTONES					
FITUSIRAN* (Sanofi)	Hemophilia	Submit NDA Filing	2024		
ELEBSIRAN* (Vir)	Chronic HBV/HDV Infection	Phase 2 Results	Q2, Q4		

* Not approved for any indication and conclusions regarding the safety or effectiveness of these drugs have not been established.
Early is Q1-Q2, Mid is Q2-Q3, and Late is Q3-Q4

Alnylam®

Alnylam 2024 Goals

		Early	Mid	Late
onpattro (patisiran) amvuttra (vutrisiran) GIVLAARI (givosiran) OXLUMO (lumasiran)	Combined Net Product Revenue Guidance to be Provided at Q4/YE 2023 Earnings			●
VUTRISIRAN			●	
ALN-TTRsc04*				●
ZILEBESIRAN*				
ALN-APP*				●
				●
ALN-KHK*				
ALN-BCAT*				
ADDITI				●
KEY PARTNER-LED PROGRAM MILESTONES				
FITUSIRAN* (Sanofi)	Hemophilia	Submit NDA Filing	2024	
ELEBSIRAN* (Vir)	Chronic HBV/HDV Infection	Phase 2 Results	Q2, Q4	

5 commercial products
(4 wholly owned)

KARDIA$_2$
Phase 2 results

HELIOS·B
Phase 3 results

6 clinical study starts

Vutrisiran sNDA filing
(assuming positive study)

3 new INDs

* Not approved for any indication and conclusions regarding the safety or effectiveness of these drugs have not been established.
Early is Q1-Q2, Mid is Q2-Q3, and Late is Q3-Q4

Alnylam®

Ambitious Five-Year Strategy to Drive Growth

Alnylam P5x25

Patients: Over 0.5 million on Alnylam RNAi therapeutics globally

Products: 6+ marketed products in rare and prevalent diseases

Pipeline: Over 20 clinical programs, with 10+ in late stages and 4+ INDs per year

Performance: ≥40% revenue CAGR through YE 2025

Profitability: Achieve sustainable non-GAAP profitability within period

Alnylam®

Thank You!

Alnylam®